Article
Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer.
Department of Oncology, Karolinska Institutet, Stockholm, Sweden.
Apmis (impact factor:
1.99).
10/2008;
116(10):888-95.
DOI:10.1111/j.1600-0463.2008.01051.x
pp.888-95
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Heat shock proteins in prostate cancer: from tumorigenesis to the clinic.
[show abstract] [hide abstract]
ABSTRACT: The heat shock proteins (HSP) constitute a superfamily of chaperone proteins present in all cells and in all cell compartments, operating in a complex interplay with synergistic/overlapping multiplicity of functions, even though the common effect is cell protection. Several reasons explain the need for investigating HSP in prostate cancer: (1) these molecules function as chaperones of tumorigenesis accompanying the emergence of prostate cancer cells, (2) they appear as useful molecular markers associated with disease aggressiveness and with resistance to anticancer therapies including hormone therapy, radiotherapy, chemotherapy and hyperthermia, and (3) they can be used as targets for therapies. The latter can be accomplished by: (i) interrupting the interaction of HSP (mainly HSPC1) with various client proteins that are protected from degradation when chaperoned by the HSP; (ii) using the chaperone and adjuvant capabilities of certain HSP to present antigenic peptides to the immune system, so this system can recognise the prostate tumour cells as foreign to mount an effective antitumoral response; and (iii) using treatment planning models taking into account the HSP expression levels to obtain more effective therapies. In summary, the study of the HSP during tumorigenesis as well as during cancer progression, and the inclusion of treatment designs targeting HSP combined with other treatment modalities, should improve prostate cancer survival in the near future.International Journal of Hyperthermia 01/2010; 26(8):737-47. · 1.92 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
289 prostate cancers
biochemical recurrence
extraprostatic extension
Gleason score
Heat shock proteins
HSP60 correlated
HSP60 staining
independent predictor
malignant tumors
median follow-up
multivariate analysis
observers
prognostic markers
prostate cancer
radical prostatectomy
Recurrence-free survival
seminal vesicle invasion
stress-associated injury
strong HSP27
tissue microarray